Serum osteoglycin level in relation to renal function and blood pressure in non-diabetic patients with hypertension

doi:10.3969/j.issn.1674-8115.2025.05.006

Abstract

Abstract:

Objective ·To investigate the association of serum osteoglycin (OGN) levels with renal function and blood pressure in non-diabetic patients with hypertension. Methods ·Hypertensive patients without a diagnosis of diabetes mellitus were recruited from the Hypertension Department of Ruijin Hospital, Shanghai Jiaotong University School of Medicine. A total of 36 renal dysfunction patients (renal dysfunction group) and 38 normal renal function patients (normal renal function group), matched for age, gender and clinic blood pressure, were included in this study. Serum OGN concentrations were measured by the enzyme-linked immunosorbent assay (ELISA). Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. The serum OGN levels were compared between the renal dysfunction group and the normal renal function group. The correlations of serum OGN level with eGFR and blood pressure were analyzed. Results ·There was no significant statistical difference in serum OGN levels between the renal dysfunction group and the normal renal function group (P=0.708). Serum OGN levels were not significantly associated with eGFR (P=0.952). In the renal dysfunction group, mean arterial pressure, age and current smoking status were relevant factors of serum OGN levels (P<0.05). After adjustment for confounders, serum OGN levels were independently associated with clinic systolic and diastolic blood pressure, 24-hour ambulatory mean systolic and diastolic blood pressure in the renal dysfunction group (P<0.05), but not in the normal renal function group (P˃0.05). Conclusion ·In non-diabetic patients with hypertension, serum OGN levels are not significantly associated with eGFR. In patients with renal dysfunction, higher serum OGN levels are independently associated with higher clinic systolic blood pressure, clinic diastolic blood pressure, 24-hour ambulatory mean systolic and diastolic blood pressure.

Key words: osteoglycin, hypertension, renal function, ambulatory blood pressure

CLC Number:

R544.1

ZHAI Wenhui, HUANG Qifang, CHEN Yilin, LI Xiaodong, WANG Jiguang. Serum osteoglycin level in relation to renal function and blood pressure in non-diabetic patients with hypertension[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(5): 578-584.

Figures/Tables 3

TrendMD

References 27

1	中国高血压防治指南修订委员会, 高血压联盟(中国), 中国医疗保健国际交流促进会高血压病学分会, 等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志(中英文), 2024, 32(7): 603-700.
	Chinese Hypertension Prevention and Treatment Guidelines Revision Committee, Chinese Hypertension League, Branch of Hypertension, China International Exchange and Promotive Association for Medical and Health Care, et al. Chinese guidelines for the prevention and treatment of hypertension (revised 2024 edition)[J]. Chinese Journal of Hypertension, 2024, 32(7): 603-700.
2	HAMRAHIAN S M. Management of hypertension in patients with chronic kidney disease[J]. Curr Hypertens Rep, 2017, 19(5): 43.
3	ZHANG L X, WANG F, WANG L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818): 815-822.
4	SEKI T, SAITA E, KISHIMOTO Y, et al. Low levels of plasma osteoglycin in patients with complex coronary lesions[J]. J Atheroscler Thromb, 2018, 25(11): 1149-1155.
5	FANG Y, CHANG Z, XU Z, et al. Osteoglycin silencing exerts inhibitory effects on myocardial fibrosis and epithelial/endothelial-mesenchymal transformation in a mouse model of myocarditis[J]. Biofactors, 2020, 46(6): 1018-1030.
6	CHENG J M, AKKERHUIS K M, MEILHAC O, et al. Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography[J]. Arterioscler Thromb Vasc Biol, 2014, 34(5): 1078-1084.
7	GU X, ZHAO L, ZHU J, et al. Serum mimecan is associated with arterial stiffness in hypertensive patients[J]. J Am Heart Assoc, 2015, 4(7): e002010.
8	ZUO Z, LI M H, ZHENG X H, et al. Elevated plasma levels of osteoglycin in cardiovascular patients: a systematic review and meta-analysis[J]. Ann Palliat Med, 2022, 11(2): 498-505.
9	WANG S, WANG Y, ZHENG R, et al. Osteoinductive factor is a novel biomarker for the diagnosis of early diabetic nephropathy[J]. Int J Clin Exp Pathol, 2015, 8(3): 3110-3115.
10	STEVENS L A, CORESH J, GREENE T, et al. Assessing kidney function: measured and estimated glomerular filtration rate[J]. N Engl J Med, 2006, 354(23): 2473-2483.
11	ZHU Y, YE X, ZHU B, et al. Comparisons between the 2012 new CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equations and other four approved equations[J]. PLoS One, 2014, 9(1): e84688.
12	LEVEY A S, STEVENS L A, SCHMID C H, et al. A new equation to estimate glomerular filtration rate[J]. Ann Intern Med, 2009, 150(9): 604-612.
13	HUANG Q F, CHENG Y B, GUO Q H, et al. Serum galectin-3 and mucin-1 (CA15-3) in relation to renal function in untreated Chinese patients[J]. Am J Hypertens, 2023, 36(3): 176-182.
14	NULALI J, ZHAN M, ZHANG K, et al. Osteoglycin: an ECM factor regulating fibrosis and tumorigenesis[J]. Biomolecules, 2022, 12(11): 1674.
15	YANG Y, WU Q H, LI Y, et al. Association of SLRPs with carotid artery atherosclerosis in essential hypertensive patients[J]. J Hum Hypertens, 2018, 32(8/9): 564-571.
16	TENGRYD C, NIELSEN S H, CAVALERA M, et al. The proteoglycan mimecan is associated with carotid plaque vulnerability and increased risk of future cardiovascular death[J]. Atherosclerosis, 2020, 313: 88-95.
17	ZUO C, LI X, HUANG J, et al. Osteoglycin attenuates cardiac fibrosis by suppressing cardiac myofibroblast proliferation and migration through antagonizing lysophosphatidic acid 3/matrix metalloproteinase 2/epidermal growth factor receptor signalling[J]. Cardiovasc Res, 2018, 114(5): 703-712.
18	STAKHNEVA E M, MESHCHERYAKOVA I A, DEMIDOV E A, et al. A proteomic study of atherosclerotic plaques in men with coronary atherosclerosis[J]. Diagnostics (Basel), 2019, 9(4): 177.
19	AL-SHARIFY D, NIELSEN S H, MATTHES F, et al. Increased proteolytic cleavage of osteoglycin is associated with a stable plaque phenotype and lower risk of cardiovascular events[J]. Atherosclerosis, 2022, 355: 8-14.
20	KUNNATHATTIL M, RAHUL P, SKARIA T. Soluble vascular endothelial glycocalyx proteoglycans as potential therapeutic targets in inflammatory diseases[J]. Immunol Cell Biol, 2024, 102(2): 97-116.
21	WEI W, TU M, HUANG R, et al. Serum osteoinductive factor is associated with microalbuminuria and diabetic nephropathy in type 2 diabetes[J]. Medicine (Baltimore), 2018, 97(31): e11759.
22	GONZÁLEZ-SALVATIERRA S, GARCÍA-FONTANA C, ANDÚJAR-VERA F, et al. Osteoglycin as a potential biomarker of mild kidney function impairment in type 2 diabetes patients[J]. J Clin Med, 2021, 10(10): 2209.
23	SCHIFFRIN E L, POLLOCK D M. Endothelin system in hypertension and chronic kidney disease[J]. Hypertension, 2024, 81(4): 691-701.
24	BARTON M, YANAGISAWA M. Endothelin: 30 years from discovery to therapy[J]. Hypertension, 2019, 74(6): 1232-1265.
25	PENG T, LI X, HU Z, et al. Predictive role of endothelin in left ventricular remodeling of chronic kidney disease[J]. Ren Fail, 2018, 40(1): 183-186.
26	REBHOLZ C M, HARMAN J L, GRAMS M E, et al. Association between endothelin-1 levels and kidney disease among blacks[J]. J Am Soc Nephrol, 2017, 28(11): 3337-3344.
27	FISCHER A, BOSSARD M, AESCHBACHER S, et al. Plasma levels of endothelin-1 and renal function among young and healthy adults[J]. Clin Chem Lab Med, 2017, 55(8): 1202-1208.

Characteristic	Renal dysfunction group (n=36)	Normal renal function group (n=38)	t/χ² value	P value
Age/year	53.5±10.4	50.8±11.1	1.07	0.287
Body mass index/(kg·m^-2)	26.0±3.5	25.3±3.2	0.89	0.375
Clinic blood pressure/mmHg
Systolic	145.6±22.6	142.0±19.3	0.74	0.459
Diastolic	87.8±17.4	85.9±14.9	0.52	0.607
Ambulatory blood pressure/mmHg
24-hour systolic	137.2±20.0	133.1±15.1	1.01	0.318
24-hour diastolic	87.1±15.1	84.8±11.2	0.76	0.453
Pulse rate/(beats·min^-1)	73.5±8.5	74.7±10.4	-0.50	0.615
Total-to-HDL cholesterol ratio	4.58±1.27	4.21±1.09	1.36	0.178
Serum LDL cholesterol/(mmol·L^-1)	3.10±0.75	2.95±0.80	0.80	0.428
Plasma fasting glucose/(mmol·L^-1)	5.48±0.63	5.59±1.07	-0.51	0.609
eGFR/[mL·(min·1.73 m²)^-1]	73.4±13.8	103.6±9.6	-10.88	<0.001
Serum uric acid/(µmol·L^-1)	399.7±100.2	311.0±92.4	3.96	<0.001
Serum hsCRP/(mg·L^-1)^①	0.99 (0.68‒2.02)	0.71 (0.42‒1.79)	0.82	0.414
Serum OGN concentration/(ng·mL^-1)	2.55±1.30	2.45±1.01	0.38	0.708
Female/n(%)	16 (44.4)	19 (50.0)	0.229	0.632
Current smoking/n(%)	12 (33.3)	13 (34.2)	0.006	0.936
Current alcohol intake/n(%)	6 (16.7)	7 (18.4)	0.039	0.843
History of cardiovascular diseases/n(%)	3 (8.3)	6 (15.8)	0.962	0.327
Use of antihypertensive drugs/n(%)	36 (100.0)	37 (97.4)	0.960	0.327
Angiotensin-converting enzyme inhibitors	9 (25.0)	6 (15.8)	0.970	0.325
Angiotensin-receptor blockers	16 (44.4)	22 (57.9)	1.339	0.247
Calcium channel blockers	31 (86.1)	29 (76.3)	1.156	0.282
Diuretics	7 (19.4)	5 (13.2)	0.538	0.463
β-blockers	15 (41.7)	15 (39.5)	0.037	0.848
Others	7 (19.4)	9 (23.7)	0.196	0.658
Albuminuria/n(%)	10 (27.8)	0 (0)	12.205	<0.001

Characteristic	Renal dysfunction group (n=36)	Normal renal function group (n=38)	t/χ² value	P value
Age/year	53.5±10.4	50.8±11.1	1.07	0.287
Body mass index/(kg·m^-2)	26.0±3.5	25.3±3.2	0.89	0.375
Clinic blood pressure/mmHg
Systolic	145.6±22.6	142.0±19.3	0.74	0.459
Diastolic	87.8±17.4	85.9±14.9	0.52	0.607
Ambulatory blood pressure/mmHg
24-hour systolic	137.2±20.0	133.1±15.1	1.01	0.318
24-hour diastolic	87.1±15.1	84.8±11.2	0.76	0.453
Pulse rate/(beats·min^-1)	73.5±8.5	74.7±10.4	-0.50	0.615
Total-to-HDL cholesterol ratio	4.58±1.27	4.21±1.09	1.36	0.178
Serum LDL cholesterol/(mmol·L^-1)	3.10±0.75	2.95±0.80	0.80	0.428
Plasma fasting glucose/(mmol·L^-1)	5.48±0.63	5.59±1.07	-0.51	0.609
eGFR/[mL·(min·1.73 m²)^-1]	73.4±13.8	103.6±9.6	-10.88	<0.001
Serum uric acid/(µmol·L^-1)	399.7±100.2	311.0±92.4	3.96	<0.001
Serum hsCRP/(mg·L^-1)^①	0.99 (0.68‒2.02)	0.71 (0.42‒1.79)	0.82	0.414
Serum OGN concentration/(ng·mL^-1)	2.55±1.30	2.45±1.01	0.38	0.708
Female/n(%)	16 (44.4)	19 (50.0)	0.229	0.632
Current smoking/n(%)	12 (33.3)	13 (34.2)	0.006	0.936
Current alcohol intake/n(%)	6 (16.7)	7 (18.4)	0.039	0.843
History of cardiovascular diseases/n(%)	3 (8.3)	6 (15.8)	0.962	0.327
Use of antihypertensive drugs/n(%)	36 (100.0)	37 (97.4)	0.960	0.327
Angiotensin-converting enzyme inhibitors	9 (25.0)	6 (15.8)	0.970	0.325
Angiotensin-receptor blockers	16 (44.4)	22 (57.9)	1.339	0.247
Calcium channel blockers	31 (86.1)	29 (76.3)	1.156	0.282
Diuretics	7 (19.4)	5 (13.2)	0.538	0.463
β-blockers	15 (41.7)	15 (39.5)	0.037	0.848
Others	7 (19.4)	9 (23.7)	0.196	0.658
Albuminuria/n(%)	10 (27.8)	0 (0)	12.205	<0.001

Blood pressure	Renal dysfunction group		Normal renal function group
Blood pressure	β±SE	P value	β±SE	P value
Clinic blood pressure/mmHg
Systolic	8.62±3.25	0.014	1.22±4.39	0.783
Diastolic	6.54±2.33	0.010	-0.58±2.41	0.813
Ambulatory blood pressure/mmHg
24-hour systolic	7.74±3.30	0.027	-1.14±2.82	0.689
24-hour diastolic	5.20±2.12	0.022	-0.81±1.76	0.651

Blood pressure	Renal dysfunction group		Normal renal function group
Blood pressure	β±SE	P value	β±SE	P value
Clinic blood pressure/mmHg
Systolic	8.62±3.25	0.014	1.22±4.39	0.783
Diastolic	6.54±2.33	0.010	-0.58±2.41	0.813
Ambulatory blood pressure/mmHg
24-hour systolic	7.74±3.30	0.027	-1.14±2.82	0.689
24-hour diastolic	5.20±2.12	0.022	-0.81±1.76	0.651

[1]	CHANG Guili, LIU Changyuan, LI Mingchun, HU Zhe, CHEN Jing, CAO Qun'an, CHU Shaoli, CHEN Xin. Relationship between non-renin-dependent aldosterone and left ventricular hypertrophy in essential hypertension [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(10): 1372-1377.
[2]	ZHANG Yiyi, NI Changyu, JIN Ying, HE Yaping, FENG Nannan. Effect of hypertension and dyslipidemia on cognition of urban elderly residents [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(7): 907-914.
[3]	FAN Qiang, WU Guangbo, ZHAO Jinbo, ZHENG Lei, LUO Meng. Research progress in pathophysiological and molecular mechanism changes during decompensated phase of portal hypertension in liver cirrhosis [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(3): 379-384.
[4]	MA Zhuoran, YUAN Ancai, JIANG Huiru, CHEN Xiaoyu, ZHANG Wei, PU Jun. Meta analysis of correlation between lipid accumulation product and hypertension in Chinese adults [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(4): 466-473.
[5]	LIU Yi-sheng1, ZHAN Yan-li2, PAN Hui1, YIN Jia-wen1, HU Yue1, CAI Xue-li2#, LIU Jian-ren1#. Comparison of outcomes after thrombectomy in patients with embolic stroke of undetermined source and cardiogenic stroke [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(9): 1270-1276.
[6]	HU Xu-lin, CHEN Yan, XIA Hong-ping, ZHANG Yong-jun. Analysis of maternal clinical risk factors for different degrees of small for gestational age infant [J]. , 2020, 40(4): 489-.
[7]	HU Zhe1, FENG Qing1, DENG Xue-qin1, HE Yan1, LI Ming-chun1, DONG Chen-jie2, HU Jing-fen3, ZHANG Nan3, GAO Yan4, CHU Shao-li1, YANG Hui1#, CHEN Xin1#. Hypertension control in Jiading, Shanghai and its relevant factors [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(12): 1652-1655.
[8]	ZHENG Lei, LIN Jia-yun, ZHANG Chi-hao, ZHAO Zhi-feng, LI Hong-jie, QI Xiao-liang, HUO Hai-zhong#, LUO Meng#. Experimental study of superior mesenteric artery remodeling in cirrhotic rats with portal hypertension [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(10): 1340-1346.
[9]	LIN Hao, PAN Jian-an, ZHANG Jun-feng, GU Jun, WANG Chang-qian. Effects of different treatment regiments for diabetes mellitus, hypertension and atrial fibrillation on the risk of heart failure with preserved ejection fraction [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(10): 1402-1407.
[10]	GAO Wei1, WANG Xue-jiao2, ZHEN Qin2, DING Xiao-ying2, XU Huan-bai2, WANG Yu-fan2, PENG Yong-de2. Analysis of risk factors of decreased heart rate variability in patients with type 2 diabetes mellitus [J]. , 2019, 39(6): 629-.
[11]	CHEN Shu-mei, WU Jia-li, LI Xiao-yan. Correlation between blood pressure and level of catecholamine in children with obstructive sleep apnea hypopnea syndrome [J]. , 2019, 39(12): 1437-.
[12]	LU Hui-ping, WU Li-na, WANG Hai-ya. Survey of self-rated health and associated factors analysis of elderly hypertensive patients in community clinics [J]. , 2019, 39(10): 1194-.
[13]	KONG Ling-yun, JIANG Geng-ru. Effect of serum IgA1 on human mesangial cells and of TGF-β1 in patients of IgA nephropathy with different renal function progress [J]. , 2018, 38(6): 647-.
[14]	XU Meng-dan, DAI Qiu-yan. Correlation of blood pressure variability with brachial ankle pulse wave velocity and left ventricular mass index [J]. , 2018, 38(2): 184-.
[15]	WU Yu-jian, SUN Kun. Progress on application of echocardiography in cardiac assessment for hypertensive children [J]. , 2018, 38(12): 1489-.